cladribine + cyclophosphamide + cytarabine + daunorubicin + dexamethasone

This is a combination chemotherapy regimen composed of five drugs: **cladribine**, **cyclophosphamide**, **cytarabine**, **daunorubicin**, and **dexamethasone**. Each drug has a distinct mechanism targeting rapidly dividing cells and disrupting various processes essential for cancer cell survival and replication: - **Cladribine**: a purine antimetabolite that integrates into DNA, leading to inhibition of DNA synthesis and repair, and induces apoptosis primarily in lymphocytes and leukemic cells[3]. - **Cyclophosphamide**: an alkylating agent that cross-links DNA strands, inhibiting DNA replication and transcription[1][8]. - **Cytarabine**: a pyrimidine antimetabolite that inhibits DNA polymerase and DNA synthesis, impeding cell division[2]. - **Daunorubicin**: an anthracycline antibiotic that intercalates into DNA and inhibits topoisomerase II, blocking DNA and RNA synthesis and generating cytotoxic free radicals[7][8]. - **Dexamethasone**: a synthetic glucocorticoid that suppresses inflammation and induces apoptosis in certain cancer cell types[1][7][8]. This drug combination is not a standard named regimen but includes agents commonly used in the treatment of **acute myeloid leukemia (AML)** and other hematologic malignancies[2][3][7][8]. Its use may be considered in aggressive or refractory leukemias where multi-agent chemotherapy is required.